Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-12-23
2010-06-29
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C435S007100, C435S006120
Reexamination Certificate
active
07745485
ABSTRACT:
Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
REFERENCES:
patent: 5726167 (1998-03-01), Dodge et al.
patent: 6020199 (2000-02-01), Monia et al.
patent: 6783760 (2004-08-01), Thorpe et al.
Gura (Science, 1997, 278:1041-1042.
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Stambolic et al., 1998, Cell, vol. 95, pp. 29-39.
Jiang et al (Feb. 15, 2002, PNAS vol. 97, pp. 1749-1753).
Hu et al (Mar. 2000, Clinical Cancer Research, vol. 6, pp. 880-886).
Schultz et al Anticancer Res. Jul.-Aug. 1995; 15(4):1135-9.
Oikawa et al (1996, European Journal of Pharmacology, vol. 318, pp. 93-96).
Hartwell et al (Science, 1997, 278:1064-1068).
Rosenzweig et al., Clin Can Res, Jul. 1997;3(7):1149-56.
Sarkaria JN et al., Cancer research (United States) Oct. 1, 1998, 58 (19) p. 4375-82, abstract only.
Yoshio et al., International Journal of Cancer 78 (5): p. 642-647 Nov. 23, 1998, abstract only.
Shibuya, Cancer Sci. Sep. 2003;94(9):751-6.
Li, Da-Ming, et al., “PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G.sub.1 cell cycle arrest in human glioblastoma cells”; Proc. Natl. Acad. Sci. USA, 95:15406-15411 (1998).
Li, Liwu, et al., “A Family of Putative Tumor Suppressors Is Structurally and Functionally Conserved in Humans and Yeast”; J. Biological Chemistry, 272: 29403-29406 (1997).
Li, Jing, et al., “PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer”; Science 275: 1943-1947 (1997).
Huang, He, et al., “PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development”, Development 126: 5365-5372 (1999).
Lee, Jie-Oh, et al., “Crystal Structure of the PTEN Tumor Suppressor: Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association”; Cell, 99; 323-334 (1999).
Sun, Hong, et al., “PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5-trisphosphate and Akt/protein kinase B signaling pathway”; Proc. Natl. Acad. Sci. USA 96: 6199-6204 (1999).
Giri, D., et al., “Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma”; PubMed, Hum. Pathol. 30:419-24 [abstract] (1999).
Zhong, H., et al., “Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol . . . ”, Cancer Res. 60:1541-1545 (Mar. 15, 2000).
Dann Dorfman Herrell & Skillman
Indiana University Research and Technology Corporation
Rigaut Kathleen D.
Yu Misook
LandOfFree
Compositions and methods for identifying agents which... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for identifying agents which..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for identifying agents which... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223807